2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)The Motley Fool · 1 day ago
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?Zacks Investment Research · 3 days ago
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?The Motley Fool · Oct 12, 2026
4 CNS Drug Stocks Worth Watching This World Mental Health DayZacks Investment Research · Oct 9, 2026
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?The Motley Fool · Oct 7, 2026
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2GlobeNewsWire · Oct 7, 2026Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.89 | -$0.99 | Miss |
| May 4, 2026 | -$0.85 | -$1.26 | Miss |
| Feb 23, 2026 | -$0.70 | -$0.71 | Miss |
| Nov 3, 2025 | -$0.82 | -$0.94 | Miss |
| Aug 4, 2025 | -$1.00 | -$0.92 | Beat |
| May 5, 2025 | -$1.26 | -$1.22 | Beat |